Increasing the Therapeutic Ratio of Radiotherapy: Cancer Drug Discovery and Development
Editat de Philip J. Tofilon, Kevin Camphausenen Limba Engleză Hardback – 25 noi 2016
Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy.
In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations.
Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection).
Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1062.48 lei 6-8 săpt. | |
Springer International Publishing – 27 iun 2018 | 1062.48 lei 6-8 săpt. | |
Hardback (1) | 1069.26 lei 6-8 săpt. | |
Springer International Publishing – 25 noi 2016 | 1069.26 lei 6-8 săpt. |
Din seria Cancer Drug Discovery and Development
- 5% Preț: 1432.61 lei
- 5% Preț: 1076.54 lei
- 5% Preț: 1375.06 lei
- 5% Preț: 1370.17 lei
- 5% Preț: 1410.57 lei
- 5% Preț: 1316.71 lei
- 5% Preț: 1398.16 lei
- 5% Preț: 1081.66 lei
- 5% Preț: 1093.93 lei
- 24% Preț: 1037.58 lei
- 5% Preț: 1424.23 lei
- 5% Preț: 1350.76 lei
- 5% Preț: 1376.82 lei
- 5% Preț: 1081.51 lei
- 5% Preț: 1387.52 lei
- 5% Preț: 1388.73 lei
- 5% Preț: 759.71 lei
- 5% Preț: 1397.27 lei
- 5% Preț: 1078.44 lei
- 5% Preț: 1393.19 lei
- 5% Preț: 1365.80 lei
- 5% Preț: 1419.11 lei
- 5% Preț: 1075.08 lei
- 5% Preț: 982.17 lei
- 5% Preț: 706.97 lei
- 5% Preț: 1331.74 lei
- 5% Preț: 1297.38 lei
- 5% Preț: 1092.33 lei
- 5% Preț: 1391.93 lei
- 5% Preț: 1079.00 lei
- 5% Preț: 1317.74 lei
- 5% Preț: 1422.82 lei
- 5% Preț: 1883.87 lei
- 5% Preț: 1377.73 lei
- 5% Preț: 1397.61 lei
- 5% Preț: 1068.70 lei
- 5% Preț: 1078.10 lei
- 5% Preț: 990.56 lei
- 5% Preț: 1401.68 lei
- 5% Preț: 1387.87 lei
- 5% Preț: 765.02 lei
- 5% Preț: 1311.70 lei
- 5% Preț: 1331.74 lei
- 5% Preț: 1081.16 lei
- 5% Preț: 1399.38 lei
Preț: 1069.26 lei
Preț vechi: 1125.54 lei
-5% Nou
Puncte Express: 1604
Preț estimativ în valută:
204.66€ • 213.30$ • 170.37£
204.66€ • 213.30$ • 170.37£
Carte tipărită la comandă
Livrare economică 06-20 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319408521
ISBN-10: 3319408526
Pagini: 318
Ilustrații: VIII, 280 p. 41 illus., 34 illus. in color.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.58 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Humana
Seria Cancer Drug Discovery and Development
Locul publicării:Cham, Switzerland
ISBN-10: 3319408526
Pagini: 318
Ilustrații: VIII, 280 p. 41 illus., 34 illus. in color.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.58 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Humana
Seria Cancer Drug Discovery and Development
Locul publicării:Cham, Switzerland
Cuprins
Part 1. Molecular Targets.- 1. Improving the therapeutic ratio of radiotherapy by targeting the DNA Damage Response.- 2. Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity.- 3. Histone Deacetylase Inhibitors and Tumor Radiosensitization.- 4. Radioprotection as a Method to Enhance the Therapeutic Ratio of Radiotherapy.- Part 2. Microenvironment.- 5. Application of Functional Molecular Imaging in Radiation Oncology.- 6. Remodeling the Irradiated Tumor Microenvironment: The 5th R of Radiobiology?.- 7. Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation.- Part 3. Clinical.- 8. Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules.- 9. Novel Imaging for Treatment Planning or Tumor Response.- 10. Increasing the Therapeutic Efficacy of Radiotherapy Using Nanoparticles.- Index.
Notă biografică
Philip J. Tofilon, Ph.D., is Senior Investigator, Radiation Oncology Branch, National Cancer Institute. Kevin Camphausen, MD, is Branch Chief, Senior Investigator, Radiation Oncology Branch, National Cancer Institute.
Textul de pe ultima copertă
Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy.
In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations.
Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection).
Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.
Caracteristici
Focuses on potential targets/strategies for increasing the therapeutic ratio for radiotherapy Discusses radiotherapies with an integrated approach Highlights advances in approaches as well as the barriers to successful clinical application Includes supplementary material: sn.pub/extras